Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Thu, 11/2/23 - 11:48 am
Tags:
Regeneron, Eylea, Roche, Vabysmo
Regeneron beats quarterly profit estimates on eczema treatment strength
Reuters
Thu, 11/2/23 - 11:33 am
Tags:
Regeneron, earnings, Dupixent
Dupixent returns as top Rx, OTC brand for September
Medical Marketing and Media
Tue, 10/17/23 - 09:41 pm
Tags:
Sanofi, Regeneron, Dupixent, DTC ads, pharma ads
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
Motley Fool
Fri, 10/6/23 - 10:05 am
Tags:
Eli Lilly, Regeneron, Novo Nordisk
Top Pharma Ad Spenders in August 2023, AbbVie Splurges to Take Top Spots
Xtalks
Sun, 10/1/23 - 01:28 pm
Tags:
pharma advertising, DTC ads, AbbVie, Skyrizi, Rinvoq, Regeneron
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Clinical Trials Arena
Fri, 09/29/23 - 11:38 am
Tags:
Regeneron, clinical trials, bispecific antibodies, linvoseltamab
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
Tags:
FDA, Sandoz, Novartis, Gilead Sciences, Pfizer, Neurocrine, Regeneron, Ipsen, Revance Therapeutics, Delcath Systems, Janssen, Galera Therapeutics, Biogen, Roche, Mesoblast, Taiho Oncology
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
BioSpace
Wed, 08/23/23 - 09:54 am
Tags:
HHS, Regeneron, JNJ, COVID-19, funding
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Mon, 08/21/23 - 10:44 am
Tags:
Regeneron, Eylea, FDA
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
BioSpace
Sun, 08/20/23 - 05:17 pm
Tags:
Regeneron, FDA, CHAPLE disease, Veopoz
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
Tags:
FDA, Ipsen, Revance Therapeutics, Neurocrine, Regeneron, palovarotene, fibrodysplasia ossificans progressiva, Daxxify, cervical dystonia, Ingrezza, chorea, Huntington's disease, pozelimab, CHAPLE disease
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Tags:
Regeneron, Eylea, age-related macular degeneration, FDA
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Wed, 08/9/23 - 10:10 am
Tags:
Regeneron, hearing loss, Decibel Therapeutics, gene therapy, M&A
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Thu, 08/3/23 - 06:40 pm
Tags:
Regeneron, Eylea, FDA
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
Thu, 08/3/23 - 11:23 am
Tags:
earnings, Moderna Therapeutics, Regeneron
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Tags:
Regeneron, prostate cancer, clinical trials, patient deaths, REGN5678, bispecific antibodies
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Tags:
Ipsen, palovarotene, fibrodysplasia ossificans progressiva, Regeneron, CHAPLE disease, pozelimab, Biomarin, Voxzogo, achondroplasia, Santhera Pharmaceuticals, vamorolone, DMD, Springworks, nirogacestat, desmoid tumors
Scratching the surface of the urticaria pipeline
EP Vantage
Thu, 07/20/23 - 10:00 am
Tags:
chronic urticaria, Sanofi, Dupixent, Regeneron, Novartis, Roche, Xolair, Allakos, AstraZeneca, Celldex Therapeutics
Dupixent goes back-to-back as top Rx, OTC pharma brand in June
Medical Marketing and Media
Thu, 07/6/23 - 10:16 am
Tags:
Dupixent, Sanofi, Regeneron
Is Regeneron's Stock in Trouble After This FDA Rejection?
Motley Fool
Thu, 07/6/23 - 10:15 am
Tags:
Regeneron, Eylea, FDA

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.